MBX Biosciences

CARMEL, IN · Founded 2019 · CIK 0001776111 · Biotech · Public

Precision therapeutics for endocrine and metabolic disorders

mbxbio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$95M
3 Form D · Nov 2022
46 months since last filing
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$23,000,000
Private capital raisedForm D · SEC$25,822,235
Private capital raisedForm D · SEC$46,675,441
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2207RJS Biologics L.L.C.——
2208TRAVERSE BIOSCIENCES, INC.——
2209ARIETIS CORPORATION——
2210MBX Biosciences—$95M
2211TECTARIA BIO LLC——
2212PARATEK PHARMACEUTICALS INC—$93M
2213Milestone Pharmaceuticals Inc.—$91M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 10 related persons
  • Tiba AynechiDirector
  • Richard BartramExecutive Officer
  • James CorneliusDirector
  • Richard DiMarchiDirector · Executive Officer
  • Carl GordonDirector
  • Peter HawrylukDirector · Executive Officer
  • Patrick HeronDirector
  • Timothy KnickerbockerDirector · Executive Officer
  • Edward MathersDirector
  • Ora PescovitzDirector

Patents

USPTO · 0 granted of 3
  • Pharmaceutical Compositions And Uses Thereofapplication
  • Pharmaceutical Compositions And Uses Thereofapplication
  • Pharmaceutical Compositions And Uses Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.